-
[show abstract]
[hide abstract]
ABSTRACT: To investigate the subjective well-being of patients with newly diagnosed multiple myeloma who were treated in a tandem transplantation programme.
Fifty-one patients participated in the prospective, longitudinal questionnaire study. The EORTC QLQ-C30 and the EuroQol-5D were administered 2 wk after completion of vincristine, adriamycin and dexamethason/vincristine, adriamycin and methyl prednison (VAD/VAMP) chemotherapy, both at hospital discharge after treatment with high-dose melphalan (HDM) and 1 month after this hospital discharge, at hospital admission, at the day of hospital discharge for peripheral stem cell transplantation (PSCT) and at 6 and 12 months following discharge after PSCT.
Overall, patients' functioning improved during treatment and follow-up, with significant decreases shortly following PSCT. Shortly after HDM and PSCT, patients reported a considerable increase in levels of soreness in the mouth (+26/+36 points on a scale ranging form 0 to 100; P < 0.01), change of taste (+23/+21 points; P < 0.05/NS), nausea/vomiting (+26/+27 points; P < 0.01/< 0.05), appetite loss (+40/+43 points; P < 0.001) and diarrhoea (+25/+36 points; P < 0.01). However, none of these symptoms persisted during follow-up.
The intensive treatment programme was subjectively being well tolerated by the majority of patients. The duration of declined quality of life after administration of HDM seemed to be short. The duration of subjective recovery after PSCT remained uncertain, but in any case was present at the 6 month follow-up. Together with the rather good results in survival, the evaluation of quality of life invites further exploration of double transplantations in multiple myeloma.
European Journal Of Haematology 03/2005; 74(2):136-43. · 2.61 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A prospective randomised phase III study in patients < or =65 years old with previously untreated multiple myeloma (MM), intensive chemotherapy followed by myeloablative chemotherapy and autologous stem-cell rescue was compared with intensive chemotherapy alone. This economic evaluation was based on detailed data from patient charts and hospital information systems. In the intention-to-treat analysis, mean total treatment and follow-up costs of the myeloablative treatment arm were 81,643 euros compared to 68,802 euros for the chemotherapy arm (P=0.09). Costs per quality-adjusted life year were 51,357 euros versus 37,328 euros. In the clinical study, no significant differences were found in overall survival after a median follow-up of 33 months from randomisation. Intensive chemotherapy is regarded as standard therapy for younger patients with previously untreated MM. Cost-effectiveness of myeloma therapy after 3 years of follow up seems not to be favoured by myeloablative treatment with autologous stem-cell rescue.
European Journal of Cancer 05/2004; 40(8):1159-69. · 5.54 Impact Factor
-
J K Doorduijn,
B van der Holt,
G W van Imhoff,
K G van der Hem,
M H H Kramer,
M H J van Oers,
G J Ossenkoppele,
M R Schaafsma,
L F Verdonck,
G E G Verhoef,
M M C Steijaert, I Buijt,
C A Uyl-de Groot,
M van Agthoven,
A H Mulder,
P Sonneveld
[show abstract]
[hide abstract]
ABSTRACT: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
Patients aged 65 to 90 years (median, 72 years) with stage II to IV aggressive NHL were randomly assigned to receive standard CHOP every 3 weeks or CHOP plus G-CSF every 3 weeks on days 2 to 11 of each cycle.
In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF. The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63). The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months. Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles). Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone. The number of hospital admissions and the number of days in hospital were not different.
In elderly patients, G-CSF improved the RDI of CHOP, but this did not lead to a higher complete response rate or better overall survival. G-CSF did not prevent serious infections.
Journal of Clinical Oncology 09/2003; 21(16):3041-50. · 18.37 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Emesis (nausea and vomiting) is one of the most important toxicities associated with chemotherapy. Although it is not life threatening, it has a major impact on a patient's health-related quality of life (HRQL) and overall response to chemotherapy. New antiemetics are expensive and well-conducted comparative health economic studies are rare. The aim of the study was to review the literature in the area of chemotherapy-induced emesis in cancer patients and to offer recommendations for the inclusion of these outcomes in the design of clinical trials for new antiemetic therapies. The economic literature was reviewed based on methodological standards for economic evaluation. Many studies did not comply with standards, specifically with regard to the choice of alternatives, chosen perspective, setting, type of emesis, measurement of costs and defining outcomes (including health-related quality of life). These issues are described for each study and recommendations for trial design are presented. The role of economic data is to support decision making in choosing between competing antiemetic therapies. It is the combination of clinical outcomes, costs and health-related quality of life, which will allow treating physicians to comprehensively assess the relative value of antiemetic therapies and to provide the most cost-effective therapy for their patients.
European Journal of Cancer 09/2000; 36(12):1522-35. · 5.54 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In the past 15 years, perspectives on treatment of patients with relapsed non-Hodgkin's lymphoma have changed. This has had important consequences for the costs of treatment. We conducted a retrospective study comparing the costs of four different treatment modalities in a university hospital in The Netherlands. The first group of patients received an autologous bone marrow transplantation (ABMT) and was kept in reverse barrier nursing. Their average total treatment costs amounted to US$26,539. Patients in the second group also received an ABMT but stayed on the normal hematology ward. The total average treatment costs for this group were US$20,806. In the third group, patients were transplanted with whole blood. Their average total treatment costs amounted to US$17,000. Patients in the fourth group received transplantation of autologous PBPC and their average total treatment costs were US$14,205. The decline in costs over time was mainly due to shorter hospitalization, less blood transfusions, and less parenteral nutrition. These factors also likely led to an improvement in patients' quality of life. The results of this study show that the progression in stem cell transplantation (SCT) techniques has been accompanied by significant benefits for patients and a decrease in costs.
Journal of Hematotherapy & Stem Cell Research 01/2000; 8(6):619-25.
-
[show abstract]
[hide abstract]
ABSTRACT: The aim of this paper is to compare the costs of autologous bone marrow transplantation (ABMT) and whole blood transplantation in patients with relapsed or poorly responding non-Hodgkin's lymphoma.
In a retrospective study, we calculated the treatment costs of 40 patients who received either ABMT or, alternatively, whole blood mobilised by filgrastim (a granulocyte colony-stimulating factor.
The recovery of granulocytes was markedly accelerated in the whole blood group as compared with the ABMT group. This resulted in a reduction in hospital costs, and costs for diagnostics and medical procedures, antibacterials, nutrition and blood transfusions. The average costs per patient in the whole blood group amounted to approximately $US16,890 as compared with approximately $US20,713 in the ABMT group (1995 values), implying a cost reduction of 18% when changing to whole blood reinfusion.
With the premise that both therapies are equivalent, it seems that whole blood transplantation is more cost effective than ABMT.
PharmacoEconomics 04/1999; 15(3):305-11. · 2.66 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In a retrospective study, we calculated the treatment and follow-up costs of patients with newly diagnosed multiple myeloma. The total treatment programme consisted of eight phases: VAD or VAMP chemotherapy, follow-up I, high-dose melphalan followed by transplantation of whole blood, follow-up II, collection of peripheral blood progenitor cells by leukapheresis, follow-up III, high-dose chemotherapy (busulfan/cyclophosphamide) followed by reinfusion of peripheral stem cells and follow-up IV (until 3 months from hospital discharge after peripheral stem cell transplantation). For each phase the average costs were calculated for all patients who were on treatment/follow-up in each particular phase. The total average cumulative costs of treatment and follow-up of all patients amounted to US$49850. Considering only the patients who completed the total treatment programme as it was scheduled, the average total treatment and follow-up costs were US$44800. The average costs of treatment and follow-up of patients who did not complete the programme as it was scheduled (patients who died, patients who were withdrawn from treatment and patients who received additional treatment) were US$57025.
Anti-Cancer Drugs 12/1998; 9(10):889-97. · 2.41 Impact Factor
-
C M Segeren,
P Sonneveld,
B van der Holt,
E Vellenga,
A.J. Croockewit,
G E Verhoef,
J J Cornelissen,
M R Schaafsma,
M.H.J. van Oers,
P W Wijermans,
W E Fibbe,
S. Wittebol,
H C Schouten,
M van Marwijk Kooy,
D H Biesma,
J W Baars,
R Slater,
M.M. Steijaert, I Buijt,
H.M. Lokhorst
-
C M Segeren,
P Sonneveld,
B van der Holt,
A.J. Croockewit,
G.E.G. Verhoef,
J J Cornelissen,
M R Schaafsma,
M.H.J. van Oers,
P W Wijermans,
W E Fibbe,
S. Wittebol,
H C Schouten,
M van Marwijk Kooy,
D H Biesma,
J W Baars,
R Slater,
M.C.M. Steijaert, I Buijt,
H.M. Lokhorst
-
